Order results by:
| Issue | Title | |
| Vol 11, No 3 (2018) | What is the role of antineoplastic drug safety in reimbursement decision making? | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev | ||
| "... . Aim: To evaluate the role of drug safety in making the decision on reimbursement. Materials ..." | ||
| Vol 9, No 1 (2016) | MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 | Abstract similar documents |
| A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum | ||
| "... in 2014 were used. In 2015 we included data on 141 drug dossiers. We analyzed the decision of the expert ..." | ||
| Vol 11, No 3 (2018) | The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia | Abstract similar documents |
| V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina | ||
| "... the principles of health technologies assessment (HTA) and the reimbursement strategies in Russia have been put ..." | ||
| Vol 12, No 2 (2019) | Health technology assessment and reimbursement of pharmaceuticals in Italy | Abstract similar documents |
| F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| "... ) is the national health technology assessment (HTA) authority in charge of the reimbursement and formulary-listing ..." | ||
| Vol 7, No 4 (2014) | APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES | Abstract similar documents |
| V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova | ||
| "... objectivity and transparency of decisions in the area of rare diseases. The main advantage of multiple ..." | ||
| Vol 12, No 4 (2019) | The health technology assessment system in Australia | Abstract similar documents |
| V. V. Omelyanovskiy, E. S. Saybel, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| "... influence the committee decision. In addition to the full reimbursement of pharmaceuticals, the committee ..." | ||
| Vol 8, No 1 (2015) | PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| L. S. Melnikova | ||
| "... are used in foreign countries at reimbursement of costs for public drug supply. The author estimates ..." | ||
| Vol 11, No 2 (2018) | Regional adaptation of the federal model of reimbursement for medical assistance based on clinical statistical groups: hospitalization of patients in need of genetically enginered biological preparations | Abstract similar documents |
| M. V. Sura, T. N. Ignatova, N. S. Rudneva, Yu. N. Sukhanova, N. G. Ulyanova, A. S. Khudyaev, V. A. Shelyakin, D. V. Scherbakov | ||
| "... ) in 2018 provides for the reimbursement for hospital stay expenses by the compulsory medical insurance fund ..." | ||
| Vol 11, No 2 (2018) | Introduction of medical products into healthcare practice and costs reimbursement: European experience | Abstract similar documents |
| V. V. Omelyanovsky, S. S. Otstavnov, N. Z. Musina, V. S. Dombrovskii | ||
| Vol 12, No 2 (2019) | Organizational structure and funding of health technology assessment agencies around the world | Abstract similar documents |
| G. R. Khachatryan, V. V. Omelyanovskiy, L. S. Melnikova, S. S. Ratushnyak | ||
| "... : «organizational structure of HTA agency», «funding of HTA agency», «pharmaceutical», «reimbursement», «healthcare ..." | ||
| Vol 13, No 3 (2020) | Evaluation of the antitumor drugs therapeutic value using the method of multicriterial analysis of decision-making | Abstract similar documents |
| V. A. Lemeshko, N. Z. Musina, V. V. Omelyanovskiy | ||
| "... on multi-criteria analysis of decision making. Materials and methods. The study included 4 main stages ..." | ||
| Vol 10, No 1 (2017) | RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION | Abstract similar documents |
| M. V. Sura | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..." | ||
| Vol 13, No 2 (2020) | Affordability of in vivo gene therapy. Problems and potential solutions | Abstract similar documents |
| V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko | ||
| "... not reveal general methodological peculiarities. The analysis of the approaches to the reimbursement ..." | ||
| Vol 10, No 3 (2017) | Review of the current approaches to the assessment of the drug innovative potential worldwide | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva, V. V. Omel’yanovskii, G. R. Khachatryan, K. V. Gerasimova, V. A. Lemeshko, K. P. Konchits | ||
| "... significance of a new medical product and make an educated decision on the reimbursement, cost and priority ..." | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... reimbursement) shows a substantial variety and presence of national peculiarities; however the majority ..." | ||
| Vol 10, No 3 (2017) | Decision modelling for the evaluation of diabetes outcomes | Abstract similar documents |
| A. A. Mosikian, W. Zhao, T. L. Galankin, A. S. Kolbin | ||
| "... The process of decision modelling in diabetes mellitus (DM) is often complicated by comorbidity ..." | ||
| Vol 5, No 1 (2012) | PHARMACOECONOMICS AS A NEW INSTRUMENT OF PHARMACEUTICAL MARKETING | Abstract similar documents |
| M. V. Protsenko, N. I. Koroleva | ||
| "... to convey to health care decision makers and how to bring this information full, correct, and easy ..." | ||
| Vol 11, No 4 (2018) | International experience in determining the cost-effectiveness thresholds | Abstract similar documents |
| T. P. Bezdenezhnykh, N. Z. Musina, V. K. Fedyaeva, T. S. Tepcova, V. A. Lemeshko, V. V. Omelyanovsky | ||
| "... ), in Australia and new Zealand. The CeT is commonly used to rationalize decision-making in health cost ..." | ||
| Vol 13, No 4 (2020) | Evaluation of the reference value of the incremental parameter "cost-effectiveness" for Russian healthcare system | Abstract similar documents |
| T. S. Teptsova, N. Z. Musina, V. V. Omelyanovsky | ||
| "... , incremental cost-effectiveness ratio) is used as one of the decision-making criteria for reimbursement in some ..." | ||
| Vol 7, No 4 (2014) | MODELING IN CLINICO-ECONOMIC ANALYSIS OF MEDICAL ORGANIZATIONAL TECHNOLOGIES | Abstract similar documents |
| M. A. Shapovalova, A. R. Umerova, V. A. Bondarev, L. R. Koretskaya | ||
| "... decision tree and Markov model we used for calculating the anticipated costs when comparing two ..." | ||
| Vol 12, No 4 (2019) | Clinical and economic analysis of drug costs in a general hospital in 2014-2018 | Abstract similar documents |
| A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova | ||
| "... with a simultaneous analysis of case histories. Results. The analysis of drug purchases in 2014-2018 and the obtained ..." | ||
| Vol 11, No 3 (2018) | Determination of a willingness-to-pay threshold and decision-making in financing the healthcare technologies | Abstract similar documents |
| T. S. Teptsova, T. P. Bezdenezhnyh, V. K. Fedyaeva, N. Z Musina, G. R. Hachatryan, V. V. Tarasov | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... . A structured interview was conducted which involved 11 experts - key participants of the drug price regulation ..." | ||
| Vol 5, No 1 (2012) | EСOLOGO-ECONOMIC PROBLEMS OF TECHNOGENIC INFLUENCE OF POLLUTION ON DISEASE OF THE POPULATION | Abstract similar documents |
| A. I. Borodin, E. M. Ovchinnikov | ||
| "... decision-making on maintenance of quality of environment ..." | ||
| Vol 10, No 2 (2017) | THE USE OF MULTI-CRITERIAL DECISION ANALYSIS (MCDA) FOR ESTIMATING THE THERAPEUTIC VALUE OF INNOVATIVE DRUGS | Abstract similar documents |
| V. K. Fedyaeva, V. V. Omelyanovskiy, N. Z. Musina, G. R. Khachatryan, O. I. Ivakhnenko | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT | Abstract similar documents |
| N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... the chances of successful result (HR=3.1 [2.0; 4.9], p=0.000). Pharmacoeconomic modelling (a decision tree ..." | ||
| Vol 8, No 2 (2015) | PRINCIPLES OF IMPORT SUBSTITUTION REGARDING DRUGS | Abstract similar documents |
| Alana Viktorovna Dzaneva, Vitalii Vladimirovich Omel'yanovskii, Saniyat Aleksandrovna Kagermazova | ||
| "... ограничительных перечней на различных уровнях системы здравоохранения. В статье рассматривается методология ..." | ||
| Vol 9, No 3 (2016) | EARLY HEALTH TECHNOLOGIES ASSESSMENT — NEW APPROACH TO IMPROVING THE EFFICIENCY OF THE MEDICAL TECHNOLOGY DEVELOPMENT PROCESS | Abstract similar documents |
| N. Z. Musina, V. V. Omelyanovskiy, A. V. Krasheninnikova | ||
| "... включения технологии (лекарственного препарата) в ограничительные перечни, а также определить приемлемую для ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... tamsulosin and solifenacin therapy, including 35,400 patients eligible for government reimbursement. Using ..." | ||
| Vol 13, No 4 (2020) | Concept of value-based healthcare | Abstract similar documents |
| N. Z. Musina, V. V. Omelyanovskiy, R. V. Gostischev, O. A. Sukhorukikh, V. K. Fedyaeva, N. N. Sisigina, D. G. Shchurov | ||
| "... processes including procurement of drugs and medical devices, their pricing, and reimbursement. ..." | ||
| Vol 12, No 2 (2019) | New framework for the development of clinical guidelines in Russia | Abstract similar documents |
| D. V. Blinov, E. S. Akarachkova, A. S. Orlova, E. V. Kryukov, D. I. Korabelnikov | ||
| "... guidelines”. In addition, we used the documents of regulatory bodies of the Russian Federation, expert ..." | ||
| Vol 9, No 2 (2016) | EVALUATION OF RATIONALITY OF EXPENSES ON TREATMENT OF SEVERE COMMUNITY-ACQUIRES PNEUMONIA IN MULTI-PROFILE HOSPITAL | Abstract similar documents |
| I. V. Demko, N. V. Gordeeva, E. N. Bochanova, N. I. Golovina, A. Yu. Kraposhina, I. A. Soloveva, E. A. Sobko, T. V. Gaygolnik, S. V. Chubarova | ||
| "... in 2004, 2011 and 2014. The frequency analysis was applied to studying the structure of the carried-out ..." | ||
| Vol 12, No 3 (2019) | Clinical and economic analysis as an instrument for harmonizing import substitution in the preferential segment of medicinal support | Abstract similar documents |
| E. V. Eliseeva , E. S. Maneeva , R. K. Goncharova , A. V. Kropotov | ||
| "... in 2014; in 2014-2015 it dropped significantly to 53.8% and 54.1%, respectively. In Region 2, the similar ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... definition of a rare disease and no universal approach to orphan drugs legislation. As a result, decision ..." | ||
| Vol 8, No 4 (2015) | APPROACHES TO THE CONCEPTS OF PRODUCTIVITY, EFFICIENCY AND EFFECTIVENESS IN THE FIELD OF SCIENTIFIC RESEARCH AND DEVELOPMENT | Abstract similar documents |
| O. F. Seliverstova | ||
| "... decision-making needs to be redressed. Recommendations on fixing these concepts in normative legal ..." | ||
| Vol 11, No 4 (2018) | Patient registers and account registries of compulsory medical insurance: integration and replaceability | Abstract similar documents |
| I. A. Zheleznyakova, G. I. Pirova, E. A. Proxorovich | ||
| "... for making organizational decisions on the healthcare system. The aim of this study is to review ..." | ||
| Vol 12, No 4 (2019) | Developing clinical guidelines and assessing the quality of medical care using the RAND/UCLA method | Abstract similar documents |
| O. O. Buzuverova, V. K. Fedyaeva, O. A. Sukhorukikh | ||
| "... to consider both the relevant scientific data and the opinion of leading experts for deciding on the specifics ..." | ||
| Vol 6, No 4 (2013) | Using indirect comparisons in pharmacoeconomic examination | Abstract similar documents |
| Yu. E. Balykina, A. S. Kolbin | ||
| "... is the data of clinical studies. The experts are interested in not only the effect of a new medical technology ..." | ||
| Vol 12, No 1 (2019) | Individual cost accounting in the management of medical organizations | Abstract similar documents |
| I. A. Zheleznyakova, L. A. Kovaleva, T. A. Khelisupali | ||
| "... a close internal management of financial activity. This function helps decision-makers: control the use ..." | ||
| Vol 5, No 2 (2012) | METHODOLOGY OF COST-UTILITY ANALYSIS IN PHARMACOECONOMICSTUDIES | Abstract similar documents |
| R. I. Yagudina, I. V. Sorokovikov | ||
| "... and appropriate treatment alternatives. All stages of cost-utility analysis and decision making algorithm ..." | ||
| Vol 9, No 2 (2016) | MANAGEMENT ASPECT OF THE PROBLEM OF NARCOTIC DRUGS USE | Abstract similar documents |
| S. Yu. Soboleva, A. V. Sobolev, I. A. Kaminskaya | ||
| "... imbalance in the system of record and control of narcotic drugs and suggests using in its decision real ..." | ||
| Vol 13, No 2 (2020) | Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871 | Abstract similar documents |
| V. V. Omelyanovskiy, E. A. Maksimkina, O. I. Ivakhnenko, M. V. Avxentyeva, M. V. Sura, G. R. Khachatryan | ||
| "... No. 871 from August 28, 2014 (with amendments from November 20, 2018). The authors analyzed the historical ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... of the official request of the Expert Board on Healthcare of the Council of the Federation Committee on Social ..." | ||
| Vol 10, No 1 (2017) | THE USE OF QALY AS AN INTEGRAL MEASURE OF EFFECTIVENESS IN THE EVALUATION OF MEDICAL TECHNOLOGIES | Abstract similar documents |
| N. Z. Musina, V. K. Fedyaeva | ||
| "... better decision-making on financing the medical treatment within a limited budget. With this algorithm ..." | ||
| Vol 8, No 3 (2015) | LEGAL REGULATION OF STATE MANAGEMENT OF MEDICAL SCIENCE | Abstract similar documents |
| L. S. Melnikova, O. Yu. Rebrova, V. V. Omelyanovskiy | ||
| "... 23 августа 1996 г. N 127-ФЗ «О науке и государственно-технической политике» (ред. от 22.12.2014 ..." | ||
| Vol 10, No 3 (2017) | Initiation and intensification of insulin therapy in patients with type 2 diabetes mellitus: a budget impact analysis | Abstract similar documents |
| E. V. Biryukova, V. I. Ignat’eva | ||
| "... created a “decision tree” model that allowed us to calculate the costs of 48-week insulin therapy in 1000 ..." | ||
| Vol 8, No 3 (2015) | RESEARCH EXCELLENCE INDEX AS INSTRUMENT OF PERFORMANCE-ORIENTED BUDGETING | Abstract similar documents |
| O. V. Bogacheva, V. E. Grigorov | ||
| "... (combining both qualitative methods and experts’ opinions) are successfully used in distribution of research ..." | ||
| Vol 10, No 3 (2017) | Comparative pharmaco-economic analysis of using enzalutamide, abiraterone and cabazitaxel in post-docetaxel castration-resistant prostate cancer patients | Abstract similar documents |
| N. K. Mazina, P. V. Mazin | ||
| "... . The pharmacoeconomic advantages of enzalutamide over the two other agents are supported by the «decision tree» model ..." | ||
| Vol 11, No 1 (2018) | CYP2D6 genotyping in the daily routine of a psychiatric hospital – pharmacoeconomic evaluation | Abstract similar documents |
| A. A. Kurylev, B. V. Andreev, A. S. Kolbin, O. V. Limankin | ||
| "... decision-making model was created. The model calculates direct medical costs for the patient care ..." | ||
| 1 - 50 of 66 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
